Literature DB >> 33104837

OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.

Xin Pang1, Sha-Sha Wang1, Mei Zhang1, Jian Jiang2, Hua-Yang Fan1, Jia-Shun Wu1, Hao-Fan Wang1, Xin-Hua Liang3, Ya-Ling Tang4.   

Abstract

BACKGROUND: CKLF-like MARVEL transmembrane domain-containing 6 (CMTM6) is a critical regulator of tumor immunology among various cancers. However, the role and underlying molecular mechanism of CMTM6 in oral squamous cell carcinoma (OSCC) progression remains unclear.
METHODS: The expression of CMTM6, PD-L1 and CD163 in OSCC tissues were detected by immunohistochemistry on tissue microarray. The effect of CMTM6 knockdown on OSCC cells and macrophage polarization were analyzed by CCK-8 assay, apoptotic assay, would-healing assay, transwell assay and qPCR. OSCC cell derived exosomes were obtained by ultracentrifugation and the mechanistic studies were conducted by qPCR and Western Blot. 4-Nitroquinoline N-oxide (4NQO) induced OSCC mice were used for verifying the effect of CMTM6 downregulation on M2 macrophage infiltration and tumor growth.
RESULTS: In OSCC samples, higher CMTM6 expression has been obviously associated with higher pathological stage of OSCC patients, CD163 + macrophages infiltration and PD-L1 expression. CMTM6 knockdown of OSCC cells inhibited proliferative, migrative and invasive abilities of OSCC cells, as well as inhibited M2 macrophage polarization in vitro with downregulating PD-L1 expression. Importantly, exosomes from OSCC cells shuttled CMTM6 to macrophages and promoted M2-like macrophage polarization through activating ERK1/2 signaling. In addition, in 4NQO-induced OSCC mice, CMTM6 level was positively associated with CD163, CD206 and PD-L1 as well as M2-like macrophage infiltration.
CONCLUSION: OSCC cell-secreted exosomal CMTM6 induces M2-like macrophages polarization to promote malignant progression via ERK1/2 signaling pathway, revealing a novel crosstalk between cancer cells and immune cells in OSCC microenvironment.

Entities:  

Keywords:  CKLF-like MARVEL transmembrane domain-containing 6; Exosome; Macrophage; Oral squamous cell carcinoma; PD-L1

Year:  2020        PMID: 33104837     DOI: 10.1007/s00262-020-02741-2

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  26 in total

1.  Expression and Clinical Significance of CMTM6 in Hepatocellular Carcinoma.

Authors:  Xiaonian Zhu; Guangzi Qi; Cong Li; Chunhua Bei; Chao Tan; Ying Zhang; Wenxiang Shi; Wen Zeng; Juan Kong; Yuanyuan Fu; Shengkui Tan
Journal:  DNA Cell Biol       Date:  2018-12-18       Impact factor: 3.311

Review 2.  Targeting tumor associated macrophages (TAMs) via nanocarriers.

Authors:  Yuvraj Singh; Vivek Kumar Pawar; Jaya Gopal Meher; Kavit Raval; Animesh Kumar; Richa Shrivastava; Smrati Bhadauria; Manish K Chourasia
Journal:  J Control Release       Date:  2017-04-01       Impact factor: 9.776

3.  Dysregulated TGF-beta1-induced Smad signalling occurs as a result of defects in multiple components of the TGF-beta signalling pathway in human head and neck carcinoma cell lines.

Authors:  Miranda Pring; Stephen Prime; E Kenneth Parkinson; Ian Paterson
Journal:  Int J Oncol       Date:  2006-05       Impact factor: 5.650

4.  An immunophenotyping of renal clear cell carcinoma with characteristics and a potential therapeutic target for patients insensitive to immune checkpoint blockade.

Authors:  Weiwei Zhao; Falin Zhao; Kai Yang; Yaxin Lu; Yuanyuan Zhang; Wenjie Wang; Hongyu Xie; Kui Deng; Chunyan Yang; Zhiwei Rong; Yan Hou; Kang Li
Journal:  J Cell Biochem       Date:  2019-03-27       Impact factor: 4.429

5.  Global DNA methylation screening of liver in piperonyl butoxide-treated mice in a two-stage hepatocarcinogenesis model.

Authors:  Atsunori Yafune; Masaomi Kawai; Megu Itahashi; Masayuki Kimura; Fumiyuki Nakane; Kunitoshi Mitsumori; Makoto Shibutani
Journal:  Toxicol Lett       Date:  2013-08-19       Impact factor: 4.372

Review 6.  Evolution of treatment and high-risk features in resectable locally advanced Head and Neck squamous cell carcinoma with special reference to extracapsular extension of nodal disease.

Authors:  Valentina Krstevska
Journal:  J BUON       Date:  2015 Jul-Aug       Impact factor: 2.533

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

8.  CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.

Authors:  Marian L Burr; Christina E Sparbier; Yih-Chih Chan; James C Williamson; Katherine Woods; Paul A Beavis; Enid Y N Lam; Melissa A Henderson; Charles C Bell; Sabine Stolzenburg; Omer Gilan; Stuart Bloor; Tahereh Noori; David W Morgens; Michael C Bassik; Paul J Neeson; Andreas Behren; Phillip K Darcy; Sarah-Jane Dawson; Ilia Voskoboinik; Joseph A Trapani; Jonathan Cebon; Paul J Lehner; Mark A Dawson
Journal:  Nature       Date:  2017-08-16       Impact factor: 49.962

9.  CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas.

Authors:  Xiudong Guan; Chuanbao Zhang; Jingyan Zhao; George Sun; Qingkun Song; Wang Jia
Journal:  EBioMedicine       Date:  2018-08-18       Impact factor: 8.143

10.  Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

Authors:  Riccardo Mezzadra; Chong Sun; Lucas T Jae; Raquel Gomez-Eerland; Evert de Vries; Wei Wu; Meike E W Logtenberg; Maarten Slagter; Elisa A Rozeman; Ingrid Hofland; Annegien Broeks; Hugo M Horlings; Lodewyk F A Wessels; Christian U Blank; Yanling Xiao; Albert J R Heck; Jannie Borst; Thijn R Brummelkamp; Ton N M Schumacher
Journal:  Nature       Date:  2017-08-16       Impact factor: 49.962

View more
  25 in total

Review 1.  CMTM6, a potential immunotherapy target.

Authors:  Jie Liang; Shaohua Li; Wei Li; Wei Rao; Shuo Xu; Haining Meng; Fengqi Zhu; Dongchang Zhai; Mengli Cui; Dan Xu; Jinzhen Cai; Bei Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2021-11-16       Impact factor: 4.553

2.  The Overexpression of Fibronectin 1 Promotes Cancer Progression and Associated with M2 Macrophages Polarization in Head and Neck Squamous Cell Carcinoma Patients.

Authors:  Wan-Hang Zhou; Wei-Dong Du; Yan-Fei Li; Maged Ali Al-Aroomi; Cong Yan; Yao Wang; Ze-Ying Zhang; Fa-Yu Liu; Chang-Fu Sun
Journal:  Int J Gen Med       Date:  2022-05-17

Review 3.  Current Status, Opportunities, and Challenges of Exosomes in Oral Cancer Diagnosis and Treatment.

Authors:  Hongyu Liu; Yisheng Huang; Mingshu Huang; Zhijie Huang; Qin Wang; Ling Qing; Li Li; Shuaimei Xu; Bo Jia
Journal:  Int J Nanomedicine       Date:  2022-06-16

4.  Protective roles of apremilast via Sirtuin 1 in atherosclerosis.

Authors:  Dongkui Sui; Hua Yu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

Review 5.  Exosomes: Potential Biomarkers and Functions in Head and Neck Squamous Cell Carcinoma.

Authors:  Ting Li; Juan Li; Haitao Wang; Jiayu Zhao; Mingze Yan; Hongjiang He; Shan Yu
Journal:  Front Mol Biosci       Date:  2022-06-14

Review 6.  CMTM6 as a master regulator of PD-L1.

Authors:  Mahmoud Mohammad Yaseen; Nizar Mohammad Abuharfeil; Homa Darmani
Journal:  Cancer Immunol Immunother       Date:  2022-03-16       Impact factor: 6.630

Review 7.  The clinical and prognostic significance of CMTM6/PD-L1 in oncology.

Authors:  Mahmoud Mohammad Yaseen; Nizar Mohammad Abuharfeil; Homa Darmani
Journal:  Clin Transl Oncol       Date:  2022-03-12       Impact factor: 3.340

8.  Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.

Authors:  Yanbin Zhao; Minghui Zhang; Haihong Pu; Shengyue Guo; Shuai Zhang; Yan Wang
Journal:  Front Oncol       Date:  2021-01-20       Impact factor: 6.244

9.  Exosomal long non-coding RNA SOX2 overlapping transcript enhances the resistance to EGFR-TKIs in non-small cell lung cancer cell line H1975.

Authors:  Dongbo Zhou; Zhi Xia; Mingxuan Xie; Ying Gao; Qiao Yu; Baimei He
Journal:  Hum Cell       Date:  2021-07-09       Impact factor: 4.174

Review 10.  Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis.

Authors:  Ioannis A Vathiotis; Georgia Gomatou; Dimitrios J Stravopodis; Nikolaos Syrigos
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.